Topping the list is Keytruda, Merck’s cancer immunotherapy, which GlobalData anticipates will reach $22.2 billion in sales by 2025.
Here is the full list:
1. Keytruda ($22.2 billion)
2. Eliquis ($18.7 billion)
3. Revlimid ($12.4 billion)
4. Opdivo ($12 billion)
5. Imbruvica ($11.9 billion)
6. Humira ($10.3 billion)
7. Biktarvy ($10 billion)
8. Ibrance ($9 billion)
9. Stelara ($7.5 billion)
10. Trulicity ($7.2 billion)
More articles on pharmacy:
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September
Novant Health to open health clinics inside Walgreens
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.